MOTS-c side effects and benefits: what the evidence shows

The short answer: no published study has measured MOTS-c side effects in people, because no study has given it to people and reported results. When FDA reviewed it for its compounding advisory committee in July 2026, it found no human exposure data by any route, no animal toxicity studies, and no reports in its adverse event database, and it concluded that the safety risks of MOTS-c in humans are unknown. [3] The benefit claims come from mouse and rat studies. [1] [2] The first randomized human trial is recruiting and has not reported. [5]

This page sets the benefit claims next to the evidence behind each one, then covers what is known and unknown about safety, and where MOTS-c stands legally. It does not give dosing; no dose has been established in people. Weight loss has its own page: MOTS-c for weight loss.

Has MOTS-c caused side effects in people?

There is no controlled record to answer from. FDA searched PubMed, Embase, Cochrane, ClinicalTrials.gov, and its own adverse event reporting system (FAERS) for its July 2026 review. It found no clinical studies, no human pharmacokinetic data, and no FAERS reports for MOTS-c through March 2025. [3]

An empty adverse event database is not a clean safety record. FDA notes that compounding pharmacies generally do not report adverse events to it, so a missing report can mean nobody filed one. [3] People who use MOTS-c outside a trial describe injection site irritation, but those are anecdotes with no denominator and no comparison group.

The animal safety record is also thin. FDA found no acute toxicity, repeat-dose toxicity, genotoxicity, reproductive toxicity, or carcinogenicity studies of MOTS-c in either form it reviewed. [3] Those are the studies a drug normally completes before it is given to people for long periods.

What side effects could MOTS-c cause?

Three concerns come up in the record. None has been measured in people.

Low blood sugar. MOTS-c increased glucose uptake into muscle and improved insulin sensitivity in mice. [1] In obese mice, a short course roughly halved blood glucose. [3] That raises a theoretical risk of hypoglycemia, which would matter most for someone also taking insulin, a sulfonylurea, metformin, or a GLP-1 medicine. No human interaction study exists. The registered phase 2a trial excludes people taking glucose-lowering drugs, so it will not answer this either. [5]

An immune reaction to the peptide. FDA said it is concerned about immunogenicity, meaning the body making antibodies against the injected peptide, when MOTS-c is given by injection under the skin. Peptides can clump together (aggregate), and aggregates and manufacturing impurities raise that risk. [3] FDA's briefing explains that immune responses to protein and peptide drugs range from antibodies with no symptoms to severe reactions, and that antibodies can in principle neutralize the body's own version of the peptide. [3] That last point is specific to a substance like MOTS-c, which your mitochondria already make. No study has tested whether injected MOTS-c triggers antibodies in people; the phase 2a trial lists anti-drug antibodies as a secondary outcome. [5]

Unknown targets. Most MOTS-c effects appear to run through AMPK, the cell's energy sensor, but FDA notes that the molecular target is still unknown, which makes it hard to predict which organs an injected dose would affect. [3]

Product quality is a separate risk from the molecule. FDA's review noted that MOTS-c is sold under inconsistent names and in two different forms, free base and acetate salt, that are not interchangeable. [3] Products labeled for research use are not checked for identity or purity, and when they are sold for human use FDA treats them as unapproved new drugs. [14]

Does injected MOTS-c even reach the body intact?

That is an open question, and it bears on both benefits and side effects. In a doping control study, MOTS-c added to human blood in the lab broke down into shorter fragments, and the researchers built their test to detect those fragments too. [4] FDA read that work as showing rapid breakdown in human blood and said it is unknown whether a dose given to a person reaches active levels over time. [3] No human pharmacokinetic study has been published. [3]

The same study found that a commercial ELISA kit reported far higher blood MOTS-c levels than mass spectrometry could confirm. [4] Keep that in mind when you read human studies that measure MOTS-c in blood: the number depends on the assay.

What benefits does MOTS-c research claim?

Each common claim traces back to animal or cell work. Here is what each one rests on.

Metabolism and insulin sensitivity. The 2015 study that named MOTS-c found that it acts mainly on skeletal muscle, activates AMPK, and protected mice from diet-induced obesity, diet-induced insulin resistance, and age-related insulin resistance. [1] A later study found that it prevented weight gain, fat build-up, and poor glucose tolerance in female mice after their ovaries were removed, a model of menopause. [9] These are the studies behind claims about blood sugar and insulin resistance. The weight question is covered in MOTS-c for weight loss.

Exercise capacity and aging. A 2021 study found that MOTS-c treatment improved treadmill running in young, middle-aged, and old mice, and that treatment started late in life improved physical capacity and some healthspan measures. [2] This is the source of the "exercise mimetic" label. FDA's summary of the same paper notes a modest lifespan gain in the late-life treated mice. [3]

Bone. In rat bone marrow stem cells in a dish, MOTS-c pushed cells toward becoming bone-forming cells. [10] In mice with bone loss caused by implanted plastic particles, local MOTS-c injections reduced bone erosion and inflammation. [11] Neither is a model of age-related bone loss in a whole animal, and no human bone study exists. The osteoporosis page covers treatments with human fracture data.

Blood vessels. In rats given vitamin D3 and nicotine to calcify their arteries, daily MOTS-c reduced vascular calcification and the heart changes that followed. [12]

FDA's assessment of this body of work: the studies were limited to rodents and cells, did not test how effect changes with dose, and their relevance to people is unknown. FDA found no clinical study of MOTS-c for any of the nominated uses, which included insulin resistance, obesity, osteoporosis, vascular calcification, and longevity. [3] A 2023 review reached a similar point from the research side, noting that no effective way to use MOTS-c in the clinic had been developed. [13]

What do human studies of MOTS-c actually show?

The human studies measure MOTS-c that the body makes. None gives the peptide as a treatment.

• Exercise raises it. In 10 healthy young men, MOTS-c rose in muscle and blood after exercise. [2]
• A gene variant is linked to diabetes. A mitochondrial DNA variant that changes one amino acid in MOTS-c was associated with type 2 diabetes in Japanese men, and the variant peptide was less active in cells. [6]
• Levels are higher in obesity. In a 2026 study, adults with obesity had higher blood MOTS-c than lean adults, and levels did not fall after bariatric surgery and large weight loss. [7]
• Levels track abdominal and liver fat. In 125 adults without diabetes, plasma MOTS-c was positively associated with abdominal and liver fat. [8]

These are associations. Higher MOTS-c in people with more metabolic stress could be the body's response to that stress, and it does not show that adding more would help. Our evidence grade for MOTS-c is animal only, and the MOTS-c entity page lists each study with its design and population.

What do MOTS-c before and after claims show?

They show what happened to one person, not what MOTS-c did. No published controlled human study has measured body weight, body fat, muscle, or appearance after MOTS-c, so there is no trial result to set a before and after photo against. The only controlled body composition data are from mice. [1] The registered phase 2a trial is recruiting and measures insulin sensitivity and adverse events, not body composition. [5]

A before and after report cannot separate the peptide from everything else, for three reasons:

• No control group. Without people who got a placebo under the same conditions, there is no way to know what would have happened anyway.
• Other changes at the same time. People who start a peptide often change diet, training, sleep, or other medicines in the same weeks, and any of those can change a photo.
• Regression to the mean. People tend to start something new when they feel or look their worst, and a measure taken at a low point tends to drift back toward average on its own.

Photos also vary with lighting, posture, time of day, and hydration, and the ones that get posted are the ones that look good. The peptide before and after explainer covers how to read these claims for any peptide, and how to read a peptide study explains what a control group adds.

Which MOTS-c benefit claims have been tested in people?

• Better insulin sensitivity: mouse studies. [1] Tested in people: a trial is recruiting.
• More endurance, slower physical decline: mouse studies. [2] Tested in people: no.
• Stronger bone: cell and mouse studies. [11] Tested in people: no.
• Healthier blood vessels: one rat study. [12] Tested in people: no.
• A known side effect profile: no data in people. [3]

What would answer the safety question?

The registered phase 2a trial is the first candidate. It plans to randomize about 120 adults with prediabetes and overweight or obesity to MOTS-c or placebo for 12 weeks, with participants and investigators blinded. Insulin sensitivity and treatment-emergent adverse events through week 16 are its primary outcomes, and anti-drug antibodies are a secondary outcome. [5] When it reports, it will be the first controlled human safety data for MOTS-c. A 12-week study of about 60 people per arm can catch common side effects; it cannot rule out rare or long-term ones.

How does MOTS-c compare with similar compounds?

MOTS-c is one of several mitochondrial-derived peptides. Our comparisons of MOTS-c vs humanin, NAD+ vs MOTS-c, and MOTS-c vs SS-31 set out what each one's evidence does and does not show, including which have human trials.

Is MOTS-c legal?

MOTS-c is not an FDA approved drug. In April 2026 FDA moved it off its 503A Category 2 list to its list of withdrawn nominations, which does not place it in any compounding category. [15] At the July 23 to 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, FDA's own briefing recommended against adding it to the 503A bulks list. [3] News reports said the committee voted in July 2026 to recommend listing it, but FDA has not posted the vote or minutes and has proposed no rule. [16] It is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. [17] Research-use-only products sold for human use are unapproved new drugs. [14]

For tested athletes, MOTS-c is prohibited at all times under WADA section S4.4, which names it as an activator of AMP-activated protein kinase. [18]

The MOTS-c regulatory timeline tracks each dated event, the MOTS-c cost page explains why there is no lawful price to compare, and the state legal guide covers how state rules interact with federal compounding law. For what the July meeting did and did not change, see the PCAC vote explained.

What this means for you

If you are weighing MOTS-c, the honest summary is that its benefits are shown in rodents and its side effects in people are unmeasured. The risks FDA named, low blood sugar, an immune reaction, and unverified product quality, are not proven harms, but nobody has run the studies that would rule them out. If you take diabetes medicine, the theoretical glucose interaction is the one to raise with a clinician first. For conditions where you want treatment with human evidence behind it, the insulin resistance and osteoporosis pages list the options that have been tested in people.